A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain

British Journal of Pharmacology

Volumn 134, Issue 8, 2001, Pages 1711-1723

  Colado, M Isabel ^a   Camarero, Jorge ^a   Mechan, Annis O ^b   Sanchez, Veronica ^a   Esteban, Blanca ^a,b   Elliott, J Martin ^b   Green, A Richard ^b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

3,4 methylenedioxymethamphetamine; Clomethiazole; Dopamine; Ecstasy; Free radicals; MDMA; Neuroprotection; Nitric oxide synthase inhibitors; NMDA antagonists; PBN

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AR R17477AR; CLOMETHIAZOLE; DIZOCILPINE; DOPAMINE; LANICEMINE; METHYL LEVO THIOCITRULLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG MECHANISM; HYPERTHERMIA; HYPOTHERMIA; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY;

ANIMALS; CHLORMETHIAZOLE; CORPUS STRIATUM; DIZOCILPINE MALEATE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEVER; FREE RADICALS; HYDROXYBENZOIC ACIDS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE; NITROGEN OXIDES; PYRIDINES; SALICYLIC ACID;

EID: 0035679302     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704435     Document Type: Article

References (76)

1. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents
2. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of neuroprotective drugs, chlormethiazole and dizocilpine
3. Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat
4. 3H]paroxetine-labeled serotonin uptake sites
5. Apparent hydroxy radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
6. Dopamine neurotoxicity: Inhibition of mitochondrial respiration
7. Further studies of the role of hyperthermia in methamphetamine neurotoxicity
8. Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration
9. Effects of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity
10. Involvement of oxidative and L-arginine-NO pathways in the neurotoxicity of drugs of abuse in vitro
11. Role of dopamine autoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced Parkinsonism
12. Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy')-induced neurodegeneration, comparison with the novel NMDA channel blocker ARR15896
13. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents neurodegeneration following administration of 'ecstasy'
14. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine
15. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
16. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine
17. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metaboliser phenotype
18. (S)-α-phenyl-2-pyridine-ethanamine dihydrochloride - A low affinity uncompetitive N-methyl-D-aspartic acid antagonist is effective in rodent models of global and focal ischemia
19. Studies on the effects of the narcotic alkaloids, cocaine, morphine and codeine on nonenzymatic lipid peroxidation in rat brain mitochondria
20. Nitric oxide, focal cerebral ischemia: Multiplicity of actions and diverse outcomes
21. Role of nitric oxide in methamphetamine neurotoxicity: Protection by nitric oxide synthase
22. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments with 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX
23. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Effects with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan
24. Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline
25. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices
26. Systemic administration of MK-801 protects against ischemia-induced hippocampal degeneration in the gerbil
27. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate; impact of methamphetamine
28. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate
29. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro
30. Clomethiazole (Zendra) in acute ischemic stroke: Basic pharmacology and biochemistry and clinical efficacy
31. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy')
32. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: Evidence for the protective effect of chlormethiazole
33. GABA potentiation: A logical pharmacological approach for the treatment of acute ischaemic stroke
34. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions
35. NMDA receptor activation produces concurrent generation of nitric oxide and reactive oxygen species: Implication for cell death
36. Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: A cautionary note visited for the third time
37. Effects of cerebral ischemia in mice deficient in neuronal nitre oxide synthase
38. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners
39. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic-neurotoxicity and peroxynitrite generation
40. Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: Protective effects of peroxynitrite decomposition catalyst
41. Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: Evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase
42. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo
43. Resistance of neuronal oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity
44. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (ecstasy)
45. The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone
46. 2+ uptake by mitochondrial inhibitors amplifies the glutamate-induced calcium response in cultured cerebellar granule cells
47. MDMA induced dopamine release in vivo: Role of endogenous serotonin
48. Adrenal and striatal tyrosine hydroxylase activity after methamphetamine
49. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies
50. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity
51. Arachidonic acid increases inositol phospholipid metabolism and glutamate release in synaptosomes prepared from hippocampal tissue
52. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
53. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity
54. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse
55. Nitric oxide: Physiology, pathophysiology and pharmacology
56. Biological reactions of peroxynitrite: Evidence for an alternative pathway of salicylate hydroxylation
57. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
58. ARL17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia
59. Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain
60. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52 week period: Part 1: Synaptosomal uptake and tissue concentrations
61. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: A consideration of dose, core temperature and dopamine synthesis
62. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine
63. Neurotoxicity of MDMA: Neurochemical effects
64. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain
65. Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity
66. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits
67. 3,4-Methylenedioxymethamphetamine (MDMA, 'ecstasy'): Pharmacology and toxicology in animals and humans
68. The effects of 3, 4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain
69. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats
70. Mammalian nitric oxide synthases
71. Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine
72. The effects of methylenedioxymethamphetamine (MDMA, 'ecstasy') on monoaminergic neurotransmission in the central nervous system
73. N-tert-butyl-alpha-phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats
74. The oxidative inactivation of mitochondrial electron transport chain components and ATPase
75. Role of brain nitric oxide in (±)3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats